ACADIA to Host Conference Call and Webcast on Monday, May 5, 2008,at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—April 28, 2008—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report its unaudited financial results for the first quarterended March 31, 2008 on Monday, May 5, 2008, after the U.S. financialmarkets close. ACADIA's management will host a conference call andwebcast on Monday, May 5, 2008, at 5:00 p.m. Eastern Time to discussACADIA's financial results and development programs.
The conference call may be accessed by dialing 800-510-0219 forparticipants in the U.S. or Canada and 617-614-3451 for internationalcallers (reference passcode 76441895). A telephone replay of theconference call may be accessed through May 19, 2008 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 30376624). The conferencecall also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archivedthere until May 19, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
(858) 558-2871
SOURCE: ACADIA Pharmaceuticals Inc.